GLP1R and metabolic dysfunction-associated steatotic liver disease: On a molecular level, GLP-1 signaling has been shown to suppress pro-inflammatory cytokine production, such as that of tumor necrosis factor-α and interleukin-6, and reduce oxidative stress, both of which contribute to hepatocellular injury and disease progression in MASLD and MetALD/ALD [70].